Infinity Pharma buys an option on future IPI-145 royalties

Infinity Pharmaceuticals (INFI +0.2%) purchases an option to buy out all future royalty payments due to Takeda's Millennium Pharmaceuticals for sales of IPI-145, Infinity's oral PI3K inhibitor.

In exchange for a one-time upfront payment of $5M, the company receives an option to terminate its obligation to Millennium future royalties related to IPI-145 in oncology. Infinity may exercise the option by providing written notice to Millennium and paying a one-time exercise fee of $52.5M on or before March 31, 2015.

Infinity will remain obligated to pay Millennium milestones related to the first two distinct PI3K product candidates that gain regulatory approval, including IPI-145. The remaining payments include up to $220M in success-based regulatory milestones, up to $230M in commercial milestones and up to $5M in development milestones.

Comments (1)
  • Betpharmgreen
    , contributor
    Comments (29) | Send Message

    4 Aug 2014, 06:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs